Table 1 Baseline characteristics and outcomes of SPIROMICS and COPDGene participants by platelet count
From: Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts
| Â | SPIROMICS | COPDGene | ||||
|---|---|---|---|---|---|---|
Characteristics [n (%) or mean ± standard deviation] | Platelet Count <350 × 109/L (n = 1696) | Platelet Count ≥350 × 109/L (n = 124) | p-value | Platelet Count <350 × 109/L (n = 2074) | Platelet Count ≥350 × 109/L (n = 111) | p-value |
Age | 65.2 ± 8 | 64.9 ± 7.6 | 0.7 | 68.3 ± 8.3 | 66.1 ± 8.6 | 0.01 |
Female | 705 (41.6) | 72 (58.1) | 0.0003 | 894 (43.1) | 72 (64.9) | <0.0001 |
Race: Black | 254 (15.1) | 21 (16.9) | 0.6 | 456 (22) | 27 (24.3) | 0.6 |
Less than high school education | 647 (38.3) | 60 (48.8) | 0.02 | 225 (10.9) | 18 (16.2) | 0.08 |
FEV1% predicted (post-bronchodilator) | 61.3 ± 23.1 | 57.3 ± 21.5 | 0.07 | 60.5 ± 22.7 | 57 ± 22.6 | 0.1 |
 GOLD I (FEV1% predicted ≥ 80%) | 380 (22.4) | 20 (16.1) | 0.2 | 432 (20.8) | 18 (16.2) | 0.2 |
 GOLD II (FEV1% predicted 50–79%) | 753 (44.4) | 55 (44.4) | 933 (45) | 50 (45.1) | ||
 GOLD III (FEV1% predicted 30–49%) | 389 (22.9) | 38 (30.7) | 508 (24.5) | 26 (23.4) | ||
 GOLD IV (FEV1% predicted < 30%) | 174 (10.3) | 11 (8.9) | 201 (9.7) | 17 (15.3) | ||
Current smoker | 569 (34.2) | 47 (38.5) | 0.3 | 679 (32.8) | 49 (44.1) | 0.01 |
Oxygen saturation ≤ 90% after 6-min walk | 541 (33.7) | 43 (38.4) | 0.3 | 653 (32.5) | 33 (30.8) | 0.7 |
Supplemental home oxygen | 391 (23.2) | 38 (30.1) | 0.05 | 512 (24.7) | 30 (27) | 0.6 |
Anemia: Hemoglobin (g/dL) <13 (men) or <12 (women) | 140 (8.3) | 20 (16.1) | 0.01 | 262 (12.6) | 35 (31.5) | <0.0001 |
At least 2 cardiovascular comorbidities | 303 (17.9) | 21 (16.9) | 0.8 | 484 (23.3) | 20 (18) | 0.2 |
 Hypertension | 853 (50.8) | 62 (50.8) | 1 | 1122 (54.2) | 64 (57.7) | 0.5 |
 Coronary arterial disease | 181 (10.8) | 5 (4.1) | 0.02 | 246 (11.9) | 4 (3.6) | 0.008 |
 Congestive heart failure | 53 (3.2) | 2 (1.6) | 0.6 | 111 (5.4) | 8 (7.2) | 0.4 |
 Diabetes | 226 (13.5) | 22 (18) | 0.2 | 353 (17) | 13 (11.7) | 0.1 |
 Stroke | 73 (4.4) | 6 (4.9) | 0.8 | 82 (4) | 3 (2.7) | 0.8 |
Body Mass Index (BMI, kg/m2) | 27.4 ± 5.3 | 27.2 ± 6.1 | 0.8 | 28 ± 6.1 | 27.2 ± 6.3 | 0.2 |
 Underweight (BMI < 18.5 kg/m2) | 62 (3.7) | 9 (7.3) | 0.1 | 56 (2.7) | 7 (6.3) | 0.06 |
 Normal/Overweight (BMI 18.5–30 kg/m2) | 1108 (65.3) | 75 (60.5) | 1355 (65.3) | 74 (66.7) | ||
 Obese (BMI ≥ 30 kg/m2) | 526 (31) | 40 (32.3) | 663 (32) | 30 (27) | ||
 Inhaled corticosteroid use | 780 (46.5) | 66 (53.7) | 0.1 | 886 (43.1) | 58 (53.2) | 0.03 |